Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979801 | 0.80 | NR3C1 (0.50) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL4983766 | 0.80 | NR3C1 (0.50) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL6397007 | 0.80 | NR3C1 (0.50) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL11588753 | 0.79 | NR3C1 (0.52) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL11588757 | 0.79 | NR3C1 (0.52) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL11589023 | 0.77 | NR3C1 (0.70) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL11589659 | 0.77 | NR3C1 (0.70) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL11589017 | 0.77 | NR3C1 (0.70) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL17451254 | 0.75 | ALDH1A1 (0.47) | NR3C1ARPGRHSD17B10TDP1 | |
| SCHEMBL14989994 | 0.75 | ALDH1A1 (0.47) | NR3C1ARPGRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S | 2008-01-31 | — | — | US | disclosed |
| EP-1148061-B1 | Epoxidation process | SEARLE LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7112669-B2 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | PHARMACIA CORPORATION (OF PFIZER, INC.) (US) | 2006-09-26 | — | — | US | disclosed |
| US-20050256094-A1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G. D. SEARLE & COMPANY (US) | 2005-11-17 | — | — | US | disclosed |
| US-6887991-B1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G. D. SEARLE & COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-6610844-B2 | Removing an 11-alpha-leaving group from an epoxymexrenone derivative | G.D. SEARLE & COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030055274-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | G.D. SEARLE & COMPANY | 2003-03-20 | — | — | US | disclosed |
| EP-0944644-B1 | PROCESSES FOR PREPARATION OF 3-KETO-7alpha-ALKOXYCARBONYL-delta-4,5- STEROIDS AND INTERMEDIATES USEFUL THEREIN | SEARLE & CO (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1223174-A2 | Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1148061-A2 | Process for preparation of 9, 11- epoxy steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2001-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256094-A1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | CYP4A11, CYP11B1, CYP17A1 | NR3C1 71/4885AR 131/4885PGR 222/4885 |
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, CYP11B1, CYP17A1 | NR3C1 89/4885AR 169/4885PGR 280/4885 |
| US-20030055274-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 45/4885AR 258/4885PGR 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.